

Screened ($n=788$)

Randomised ($n=416$)

Indacaterol 150 μg ($n=211$)

Completed ($n=186$)

Discontinued ($n=25$)

Primary reason for discontinuation

- Protocol deviation ($n=7$)
- AEs ($n=6$)
- Withdrew consent ($n=5$)
- Lost to follow-up ($n=3$)
- Administrative problems ($n=3$)
- Unsatisfactory therapeutic effect ($n=1$)

Placebo ($n=205$)

Completed ($n=178$)

Discontinued ($n=27$)

Primary reason for discontinuation

- Protocol deviation ($n=9$)
- AEs ($n=3$)
- Withdrew consent ($n=4$)
- Lost to follow-up ($n=2$)
- Unsatisfactory therapeutic effect ($n=6$)
- Not stated ($n=1$)
- Abnormal test procedure result(s) ($n=1$)
- Death ($n=1$)